Search results
Results from the WOW.Com Content Network
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
Acuitas Therapeutics Inc. is a Canadian biotechnology company based in Vancouver, British Columbia.The company was established in February 2009 to specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticle (LNP) technology, a key component of the mRNA vaccines deployed for COVID-19.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
Nasdaq Canada is a wholly owned subsidiary of the Nasdaq Stock Market Inc. and was created to extend Nasdaq's North American trading platform in Canada.Nasdaq Canada exists to enhance and ensure Canadian investors immediate trading access (including real time availability of all relevant data) of all Nasdaq securities and issuers with the ability to raise capital more efficiently.
After the FDA put the company's gene-editing product candidate for sickle cell disease on hold, bargain hunters may want to scoop up some shares. Here's why. Is Crispr Therapeutics Stock a Bad ...
The pharmaceutical industry in Canada employs approximately 30,000 people. It supplies about one third of the domestic pharmaceutical consumer market of $27 billion annually. [1] This accounts for ~16% of yearly health expenditures. Canada had a pharmaceutical trade deficit of $8.5 billion in 2018 with exports of $11 billion and imports of $19. ...